Korea Lidocaine Hydrochloride 1% Injection

Adult administration

Epidural anesthesia: 100-200 mg (maximum single dose of 200 mg) Nerve block anesthesia: 30-200 mg (30-100 mg for supportive nerve block, up to 50 mg for nerve root block) Infiltration anesthesia: 20-200 mg Surface anesthesia: appropriate amount applied or sprayed Clinical use Intravenous single administration: 50-100 mg (1-2 mg/kg) administered slowly by intravenous injection over 1-2 minutes Readministration of the same amount is possible after 5 minutes if necessary. Expected maintenance of effect

This drug should not be used in patients with intoxication, bleeding, or shock status during epidural anesthesia. It is also safer not to administer it to patients with inflammation at the injection site or nearby, or to patients with sepsis. Patients with allergies to this drug or similar amide local anesthetics should avoid its use. It should be used cautiously in patients with central nervous system diseases, pregnant women, the elderly, patients with severe hypertension, and those with spinal deformities. During administration, symptoms of shock such as hypotension, facial pallor, abnormal pulse rate, and respiratory depression may occur, so careful observation is necessary. Rarely, malignant hyperthermia symptoms such as rapid temperature rise and muscle rigidity may occur; if such symptoms appear, administration must be stopped immediately and specialized treatment is required. Signs of toxicity, such as tremors or convulsions, may appear; if these symptoms occur, administration should be stopped immediately and appropriate treatment pursued. Symptoms such as drowsiness, anxiety, dizziness, and nausea may also arise, so be attentive to these changes. Hypersensitivity reactions such as skin rash or swelling may occur; if any abnormal symptoms arise, immediate notification is necessary. It is important to prepare for immediate emergency treatment when using this drug. During administration, the lowest concentration and minimum dosage possible should be used, and it must be confirmed that the injection needle has not entered a blood vessel. Careful attention should be taken when using this drug in combination with vasoconstrictors as side effects may occur in certain patient populations. Its safety in pregnant women has not been established, so administration should be considered only after thoroughly weighing the necessity and risks involved. The elderly may be more sensitive to this drug and vasoconstrictors; therefore, dosage adjustment and condition monitoring may be necessary. It is preferable not to use this drug for ophthalmic purposes. Long-term high-dose administration should be avoided, as the metabolites of this drug may have mutagenic potential. In clinical use, it should not be administered to patients with severe cardiac conduction disturbances or those allergic to this drug. Caution should be exercised in patients with poor cardiac function, severely impaired liver or kidney function, those in shock, and the elderly. In cases of overdose, there is a risk of cardiac arrhythmias, hypotension, and cardiac arrest; therefore, continuous ECG and blood pressure monitoring are necessary during administration. There may be interactions with other medications, so consultation with healthcare professionals is essential. This drug is primarily metabolized in the liver, so special caution should be taken when administering it to elderly patients with impaired liver function.

Serious side effects

Hives, swelling, facial pallor, hypotension, respiratory depression, malignant hyperthermia (tachycardia, arrhythmias, blood pressure fluctuation, rapid temperature rise, muscle rigidity, cyanosis, hyperventilation, sweating, acidosis, hyperkalemia, red urine), anaphylactic reaction, shock, symptoms of toxicity (convulsions), cardiac arrest

Mild side effects

• Tremors
• drowsiness
• anxiety
• agitation
• confusion
• dizziness
• nausea
• vomiting
• hallucinations
• euphoria

This drug should be stored in a sealed container to prevent exposure to air, and it is recommended to keep it at a temperature between 1°C and 30°C at room temperature. This storage practice can help maintain the drug's effectiveness and prevent degradation.

Appearance

A colorless and transparent solution filled in a colorless transparent vial.

Package unit

10 vials/box [(20 mL/vial)]